Clinical Trials

210 enrolled

Multiple Myeloma

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

125 enrolled

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04512235 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

281 enrolled

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT05552976 2026-03-17

SUCCESSOR-2

525 enrolled

Multiple Myeloma, Recurrence

NCT04181827 2026-03-16

CARTITUDE-4

419 enrolled 10 charts

Multiple Myeloma

NCT04923893 2026-03-13

CARTITUDE-5

743 enrolled

Multiple Myeloma

NCT06577025 2026-03-13

aMMbition

43 enrolled

Multiple Myeloma

NCT03984097 2026-03-10

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

50 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06104449 2026-03-06

MK-5684-005

6 enrolled

Genitourinary

Prostatic Neoplasms

NCT04663347 2026-03-03

EPCORE™ NHL-2

543 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05090566 2026-02-23

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

46 enrolled 15 charts

Multiple Myeloma

NCT06136598 2026-02-17

MK-5684-001

14 enrolled

Genitourinary

Prostatic Neoplasms

NCT04162210 2026-02-11

DREAMM-3

325 enrolled 10 charts

Multiple Myeloma

NCT03652064 2026-01-20

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 1 FDA

Multiple Myeloma

NCT05455320 2026-01-16

MonumenTAL-3

864 enrolled

Multiple Myeloma, Recurrence

NCT05704049 2025-12-29

IZALCO

118 enrolled

Multiple Myeloma

NCT04910568 2025-12-24

CAMMA 1

126 enrolled

Multiple Myeloma

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

283 enrolled

Multiple Myeloma, Neoplasms

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

337 enrolled

Multiple Myeloma

NCT04091126 2025-11-28

DREAMM 9

118 enrolled

Multiple Myeloma

NCT04126200 2025-11-06

DREAMM5

208 enrolled

Multiple Myeloma

NCT04756726 2025-09-10

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

224 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT07150104 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

14 enrolled

Multiple Myeloma

NCT05308654 2025-08-14

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

34 enrolled

Multiple Myeloma, Neoplasms

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

120 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04975997 2025-07-10

EXCALIBER-RRMM

864 enrolled

Multiple Myeloma

NCT04458831 2025-06-27

IONA-MM

Active not recruiting

583 enrolled

Multiple Myeloma

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

265 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT06956170 2025-06-11

DREAMM 8

21 enrolled 9 charts

Multiple Myeloma

NCT02719613 2025-06-05

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

67 enrolled

Multiple Myeloma

NCT06868667 2025-05-09

DREAMM 7

24 enrolled 10 charts

Multiple Myeloma

NCT06163898 2025-04-04

A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

156 enrolled

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

302 enrolled 10 charts

Multiple Myeloma

NCT05669989 2025-01-23

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Multiple Myeloma

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

73 enrolled

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

424 enrolled

Multiple Myeloma, Recurrence

NCT03319667 2024-11-27

IMROZ

475 enrolled 1 FDA

Multiple Myeloma

NCT04246047 2024-10-24

DREAMM 7

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT02773030 2024-06-25

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

466 enrolled

Multiple Myeloma, Recurrence

NCT03651128 2022-12-15

KarMMa-3

381 enrolled